Greycroft.com · 18 November 2026

Programmable Biology: Investing in Boltz’s Series A

Greycroft.com

Greycroft announces its investment in Boltz's $110M Series A, a biomolecular AI company whose models predict protein-molecule interactions at AlphaFold3-level accuracy, enabling pharma to shift drug discovery from wet-lab iteration to computational design.

Read the full post on Greycroft.com ↗

Topics: Biotech & Life Sciences · AI Infrastructure

Published by Greycroft.com · their site ↗

More from Greycroft.com

SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.